...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Olmesartan in Management of Proteinuria
【24h】

Olmesartan in Management of Proteinuria

机译：奥美沙坦治疗蛋白尿

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Proteinuria is a marker and predictor of cardiovascular morbidity and mortality. Blockade of angiotensin receptor might result in reduction in proteinuria. Olmesartan, an Angiotensin Receptor Blocker (ARB) which is approved for the treatment of hypertension is believed to produce antiproteinuric effects through different mechanisms. The objective of this review is to assess the cause, duration and degree of proteinuria and understand the current place of olmesartan in management of proteinuria associated with Cardiovascular Disease (CVD) and hypertension. We performed a comprehensive search of MEDLINE, PubMed and Google Scholar databases for articles related to Olmesartan and proteinuria (till June 2017).Angiotensin-II induces transforming growth factor-? upregulation and increase transcapillary pressure. AT-I receptor blocked by olmesartan result in reduction in proteinuria. Olmesartan significantly reduces Blood Pressure (BP) and delays the onset of Chronic Kidney Disease (CKD), it also delayed the risk of onset of microalbuminuria. Olmesartan have nephroprotective, antioxidant, antifibrotic activities and proteinuria reducing effects which can be beneficial in patients with hypertension. Olmesartanis believed to produce antiproteinuric effects through different mechanisms. It is indicated for treatment of hypertension to reduce the risk of fatal and non fatal CV events which may or may not be associated with proteinuria.
机译：蛋白尿是心血管疾病发病率和死亡率的标志物和预测指标。血管紧张素受体的阻断可能导致蛋白尿减少。据信奥美沙坦是一种被批准用于治疗高血压的血管紧张素受体阻滞剂（ARB），可通过不同的机制产生抗蛋白尿作用。这篇综述的目的是评估蛋白尿的原因，持续时间和程度，并了解奥美沙坦在与心血管疾病（CVD）和高血压相关的蛋白尿管理中的当前地位。我们对MEDLINE，PubMed和Google Scholar数据库进行了全面搜索，查找与奥美沙坦和蛋白尿有关的文章（至2017年6月）。血管紧张素II诱导转化生长因子-？上调并增加跨毛细血管压力。奥美沙坦阻断的AT-1受体导致蛋白尿减少。奥美沙坦显着降低血压（BP）并延迟慢性肾脏病（CKD）的发作，也延迟了微量白蛋白尿的发作风险。奥美沙坦具有肾保护，抗氧化剂，抗纤维化活性和减少蛋白尿的作用，对高血压患者可能有益。 Olmesartanis被认为可以通过不同的机制产生抗蛋白尿作用。适用于治疗高血压，以减少致命性和非致命性CV事件的风险，这种风险可能与蛋白尿有关，也可能不与蛋白尿有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号